

Trovogene, Inc.
Form 8-K
August 09, 2016

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **August 9, 2016**

Trovogene, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation or organization)

001-35558
(Commission File
Number)

27-2004382
IRS Employer
Identification No.)

11055 Flintkote Avenue, Suite A

San Diego, CA 92121

(Address of principal executive offices)

Registrant's telephone number, including area code: **(858) 952-7570**

(Former name or former address, if changed since last report)

Edgar Filing: Trovagene, Inc. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events.

On August 9, 2016, Trovogene, Inc. (the Company) issued a press release announcing that a patient case report featuring use of the Company's Trovera EGFR urine-based liquid biopsy test was recently published in *Experimental Hematology & Oncology*. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

In addition, on August 9, 2016, the Company issued a press release announcing that it is scheduled to attend the 2016 Avondale Partners Healthcare 1-1 Conference on Wednesday, August 10, 2016 at the Boston Harbor Hotel, in Boston, Massachusetts. A copy of the press release is furnished as Exhibit 99.2 to this Form 8-K.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

- 99.1 Press Release of Trovogene, Inc. dated August 9, 2016
- 99.2 Press Release of Trovogene, Inc. dated August 9, 2016

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 9, 2016

TROVAGENE, INC.

By: /s/ William J. Welch
William J. Welch
President and Chief Executive Officer